
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf has reported a strong growth trajectory, particularly in its Retail segment, with revenues reaching $255 million, reflecting an 8.1% quarterly increase and a 7.8% annual increase, alongside expanding gross margins. The company is expected to achieve free cash flow guidance of $190 million to $210 million by 2025, nearly doubling from $109 million in 2024, and it has delivered positive free cash flow for four consecutive quarters, underscoring its financial stability. Additionally, projected year-over-year EPS growth in 2026 is expected to be robust, supported by revenue growth and targeted improvements in gross and operating margins.
Bears say
Diebold Nixdorf Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from technological shortcomings and reduced demand for its products, which are exacerbated by increasing competition and pricing pressures. The company's Banking segment has reported a slight decline in gross margins to 26.8%, indicating potential difficulties in maintaining profitability amidst these market pressures. Additionally, ongoing risks such as tariff-related costs, supply chain disruptions, and liquidity issues further complicate the company's financial stability and forecasted performance.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares